Neonatal Neurobehavior, Medical Risk, and 2-year Developmental Outcomes in Infants Born Gestation
Elizabeth C. McGowan, Barry M. Lester(Providence College), Howard W. Kilbride(Children's Mercy Hospital), Marie Camerota(Providence College), Steven L. Pastyrnak(Spectrum Health), Lynne M. Smith(UCLA Medical Center), Michael O’Shea, Lynne M. Dansereau(Providence College), Sheri A. DellaGrotta(Providence College), Brian S. Carter(American Cancer Society), Jennifer Helderman(Atrium Health Wake Forest Baptist), Jennifer Check(Wake Forest University), Charles R. Neal(University of Hawaiʻi at Mānoa), Julie A. Hofheimer(University of North Carolina at Chapel Hill)
Unknown
January 1, 2021
Cited by 0
Related Papers
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
The Maternal Lifestyle Study: Drug Use by Meconium Toxicology and Maternal Self-Report
|PEDIATRICS|2001|307
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome
|Drug and Alcohol Dependence|2005|295
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma
|JAMA Oncology|2020|251
Methamphetamine and Other Substance Use During Pregnancy: Preliminary Estimates From the Infant Development, Environment, and Lifestyle (IDEAL) Study
|Maternal and Child Health Journal|2006|221